Synlogic (NASDAQ:SYBX) Stock Price Down 0.7% – Here’s What Happened

Shares of Synlogic, Inc. (NASDAQ:SYBX) fell 0.7% during mid-day trading on Thursday . The stock traded as low as $1.44 and last traded at $1.52. 103,418 shares changed hands during trading, an increase of 100% from the average session volume of 51,819 shares. The stock had previously closed at $1.53.

Synlogic Price Performance

The company has a market capitalization of $17.55 million, a PE ratio of -0.36 and a beta of 0.83. The stock has a 50-day simple moving average of $1.43 and a 200 day simple moving average of $1.50.

Synlogic (NASDAQ:SYBX) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.17. Synlogic had a negative net margin of 2,284.65% and a negative return on equity of 207.84%. As a group, research analysts predict that Synlogic, Inc. will post -2.71 EPS for the current fiscal year.

Synlogic Company Profile

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.